Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Semantix in connection with acquisition of INK Norge AS
Mandate

Vinge advises Semantix in connection with acquisition of INK Norge AS

December 09, 2010

Vinge has advised Semantix, Litorina's portfolio company, in connection with its acquisition of INK Norge AS, a leading supplier of translation services in Norway.

The acquisition has strengthened Semantix's leading position within the language services industry in the Nordic countries. INK Norge AS was founded in 1987 and is one of Norway's leading translation agencies with customers primarily in the private sector including Nowegian and international companies which require expert translation services. INK Norge AS offers both translation services and copywrighting and editorial language services.

Vinge's team consisted of responsible partner Johan Winnerblad and associate Alexandra Kempe.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024